<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373176</url>
  </required_header>
  <id_info>
    <org_study_id>CTN401614102</org_study_id>
    <nct_id>NCT02373176</nct_id>
  </id_info>
  <brief_title>[14C] Icosabutate -A Phase I Absorption, Metabolism and Excretion Study</brief_title>
  <official_title>[14C] PRC-4016 (Icosabutate) - A Phase I, Open-label Study of the Absorption, Metabolism and Excretion Following Oral Dosing to Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pronova BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pronova BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      [14C]PRC-4016 (Icosabutate) - A Phase I, Open-Label Study of the Absorption, Metabolism and&#xD;
      Excretion Following Oral Dosing to Healthy Male Subjects.&#xD;
&#xD;
      Objective: To evaluate the pharmacokinetics of total radioactivity in blood and plasma and&#xD;
      PRB-01022 (icosabutate) (unchanged drug) in plasma following a single oral administration of&#xD;
      [14C]PRC-4016 to healthy male subjects.&#xD;
&#xD;
      To obtain a mass balance of oral [14C]PRC-4016 by quantifying the urinary and faecal&#xD;
      excretion of radioactivity.&#xD;
&#xD;
      To examine the profile of metabolites in plasma, urine and faeces. To further assess the&#xD;
      safety and tolerability of a single oral dose of [14C]PRC 4016 in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve for total 14C labelled PRC-4016 in whole blood and plasma.</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
    <description>Blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma concentration of 14C labelled PRC-4016 (icosabutate)</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
    <description>Blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantifying urinary and faecal excretion of 14C labelled PRC-4016</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
    <description>Urine- and faecal collection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability of a single dose oral 14C PRC-4016 (icosabutate)</measure>
    <time_frame>During entire study, screening till Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>[14C] PRC-4016 (Icosabutate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational medicinal product (IMP), [14C] PRC-4016 (Icosabutate) solution (600 mg in 2 mL, 200.0 Î¼Ci [7.4 MBq]). The radiochemical purity of [14C]PRC-4016 will be at least 97%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]PRC 4016 (Icosabutate)</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>[14C] PRC-4016 (Icosabutate)</arm_group_label>
    <other_name>Icosabutate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  males&#xD;
&#xD;
          -  any ethnic origin&#xD;
&#xD;
          -  age 35-60&#xD;
&#xD;
          -  BMI 18-35 kg/m2&#xD;
&#xD;
          -  generally in good health&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subjects or subjects partners not willing to use appropriate contraception&#xD;
&#xD;
          -  subjects who have received prescribed systemic or topical medication within 14 days of&#xD;
             dosing&#xD;
&#xD;
          -  subjects who have used non-prescribed systemic or topical medication within 7 days of&#xD;
             dosing&#xD;
&#xD;
          -  subjects who have received any medication incl. St. Johns Worth within 30 days of dose&#xD;
             administration.&#xD;
&#xD;
          -  subjects participating in clinical trial currently or within past 3 months.&#xD;
&#xD;
          -  recent blood donation&#xD;
&#xD;
          -  history of drug allergy or clinically significant allergic disease&#xD;
&#xD;
          -  BP and pulse outside reference range&#xD;
&#xD;
          -  high consumption of alcohol&#xD;
&#xD;
          -  high consumption og tobacco&#xD;
&#xD;
          -  clinically significant disorder or clinically significant disease within 4 weeks of&#xD;
             dosing.&#xD;
&#xD;
          -  serum hepatitis, HIV or abnormal ECG&#xD;
&#xD;
          -  subjects exposed to radiation as a result of their occupation&#xD;
&#xD;
          -  subjects who have received radiolabelled material within 12 months&#xD;
&#xD;
          -  subjects earlier taken part in the study or withdrawn from study ot not suitable for&#xD;
             enrolment according to investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Bush, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical research Unit (CRU) Ltd,Springfield House, Hyde street</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>February 20, 2015</last_update_submitted>
  <last_update_submitted_qc>February 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

